Occidiofungin
Occidiofungin is Sano's lead drug compound and is a first-in-class compound which utilizes a novel mechanism of action. Occidiofungin exhibits potent activity against an array of drug-resistant pathogens. Given its spectrum of activity, it is under investigation as a cure for recurrent vulvovaginal yeast infections. Occidiofungin is also under development as a new and effective treatment for nipple thrush as well as other dermal fungal infections that affect millions of women each year.
What is Occidiofungin?
Occidiofungin is a natural product and is isolated from a bacterial strain that was shown to prevent plant fungal diseases.
​
After being cultivated at our facilities with patented technology, occidiofungin is extracted and purified. The compound is rapidly fungicidal and is active against drug resistant fungi.
Occidiofungin is being studied for the treatment of recurrent vulvovaginal candidiasis (RVVC) in adult women. Currently, our drug has completed nonclinical studies which indicate safety and efficacy in animals, and the INDA for Phase I clinical trials has been approved by the FDAs in humans.
Treatment for Chronic Yeast Infections
Vaginal Yeast Infections
Increasingly, drug resistant and persistent yeast infections are posing an increasing challenge for millions of women finding an effective treatment. Occidiofungin is expected to provide rapid relief and cure for vaginal yeast infections. Over 100 million women have recurrent vaginal yeast infections and are in need of a safer and effective treatment. Intravaginal formulation provides a safer and more effective treatment by treating the site of infections without the unwanted systemic side effects associated with other ineffective treatment options.